Valproate vs RISPERIDONE: Dropout
Valproate showed no clear difference in dropout rate ‐ All‐cause (secondary acceptability outcome) At 5 ‐ 12… compared with risperidone (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Valproate vs risperidone Dropout rate ‐ All‐cause (secondary acceptability outcome) At 5 ‐ 12 weeks · Children and adolescents with acute mania Valproate showed no clear difference in dropout rate ‐ All‐cause (secondary acceptability outcome) At 5 ‐ 12… compared with risperidone (low certainty). Valproate for acute mania (2019) · Cochrane Headline outcomes only | OR 1.96 [1, 3.82] | 2 studies · 236 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Valproate for acute mania 2019 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.